Geron is also testing the drug for myelofibrosis (MF), another form of bone marrow cancer, and expects data from the phase 3 IMpactMF trial of imetelstat in relapsed/refractory MF in 2024.

Shares of Geron (NASDAQ:GERN) plunged 30% Wednesday after management reportedly indicated on the company's Q4 earnings call that sales of its lead drug Rytelo appear to be slowing. For Q4 ...

Geron (NASDAQ: GERN) stock is getting crushed in Wednesday's trading. The company's share price was down 31.7% as of 3:50 p.m. ET and had been down as much as 38.7% earlier in the session.

Scotiabank analyst Greg Harrison maintained a Buy rating on Geron (GERN – Research Report) today and set a price target of $4.00. The company’s shares closed yesterday at $1.60. Effectively ...